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235 U (108)/200 U (100-440) was injected. Based on a BoNT-A injection interval of 12 
weeks, the annual cost per patient in the UK would be 1,068 GBP for abobotulinum-
toxinA, 1,198 GBP for onabotulinumtoxinA and 1,399 GBP for incobotulinumtox-
inA. ConClusions: Considering the real life practice of BoNT-A injections and the 
comparison of treatment groups treated for the same limb segment, this analysis 
suggests that the use of abobotulinumtoxinA would result potentially in a reduction 
in the health care cost for the treatment of spasticity and that more patients could 
be treated with abobotulinumtoxinA with a given budget.
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objeCtives: The objective is to compare the hospitalization length of stay and 
costs associated with comorbidities between dialysis patients and non-dialysis 
patients. Methods: This was a cross-sectional observational study (from January 
to December 2010) of a national hospitalization database from the Brazilian Unified 
Public Healthcare System (Sistema Único de Saúde – SUS). Patients included in 
the study were hospitalized due to 3 predefined comorbidities categories: heart 
disease, vascular disease, and osteometabolic diseases, identified using ICD-10 
codes. Results: A total of 491,644 admissions were observed in patients not on 
dialysis (control group), while 2,627 admissions were identified in dialysis patients. 
The comparative analysis of causes of hospitalization showed that a larger propor-
tion of admissions due to heart disease was observed in patients on dialysis (61%) 
compared to the control group (47.9%), the opposite was observed for vascular and 
osteometabolic hospitalizations. For all 3 categories, cost of hospitalization for dialysis 
patients is at least two-fold higher and the length of stay almost 3 times longer (21 
days for dialysis patients versus 8 days for non-dialysis) than non-dialysis patients. 
The greatest differences between these two patient populations are in average costs 
among dialysis patients hospitalized for osteometabolic disorders versus control 
group and the highest burden regarding length of hospital stay, due to heart dis-
ease. ConClusions: There is a high hospitalization burden among CKD-5D patients 
in the Brazil health care system. Since inpatient costs were the key cost drivers for 
CKD, strategies that reduce the risk of hospitalization and increase prevention of 
comorbidities may substantially decrease the overall health care economic burden.
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objeCtives: Ankle sprains and fractures are common injuries affecting many 
individuals, often requiring substantial and costly medical interventions. Ankle 
injuries can have significant physical and economic consequences. Therefore, the 
objectives of this study were to systematically review and describe the literature 
on the direct and indirect costs related to the diagnosis and treatment of ankle 
sprains and fractures. Methods: A systematic literature review of Ovid MEDLINE, 
EMBASE, Cochrane DSR, ACP Journal Club, AMED, Ovid Healthstar, and CINAHL was 
conducted for English-language studies on ankle sprains and fractures published 
from January 1980 to December 2013. Two reviewers assessed the articles for study 
quality using available giudelines and abstracted the data. Results: Overall, 1,415 
studies were identified of which 16 were selected for analysis. A majority of the 
studies were published in the last decade. The costs of ankle sprain diagnosis and 
management ranged from $495 to $4,667 per patient (2014 USD). The costs of stable 
ankle fracture diagnosis and management ranged from $89 to $602 per patient. 
However, the management costs were higher for unstable ankle fractures ($2,680 
to $15,095) and open fractures and varied depending on the severity of injury. The 
economic evaluations were conducted from the societal or health care system per-
spective. ConClusions: The costs of diagnosing and treating ankle sprains and 
fractures varied among the studies mostly due to differences in injury severity 
and the study characteristics. Future studies undertaking economic evaluations 
should follow the available guidelines and ensure that their methods are transpar-
ent and understandable especially the study perspective and the valuation of the 
costs and outcomes.
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objeCtives: The aim of the study is to estimate the pension costs (social secu-
rity system in Italy is financed by public expenditure) induced by patients with 
musculoskeletal disorders (MD) and specifically for rheumatoid arthritis (RA), 
ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in Italy, between 2009 and 
2012. Methods: We analysed the database of National Institute of Social Security 
(INPS) to estimate for MD, RA, AS and PsA, the total costs of for three types of 
social security benefits: disability benefits (for people with reduced work ability), 
disability pensions (for people who are not eligible to be considered as workers) 
and incapacity pensions (for people without work ability). Also was estimated the 
productivity loss for RA in the 2013 with data from the National Institute of Statistics 
and from national literature review. Results: From 2009 to 2012 were paid about 
320 thousand benefits at a cost of approximately € 1.7 billion, for an average of just 
over 80,000 performances a year with a cost of € 432 million per year. Specifically 
the total pension burden for RA was about € 99 million, for AS was € 26 million and 
for PsA was € 12 million. The loss of productivity for AR in 2013 amounted to € 
707,425,191 due to 162,360 workers with RA that determine 9,174,221 working days 
ages because of the disease’s symptoms and variability, leading to reduced social 
engagement. *exchange rate: 303,59HUF/EUR
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objeCtives: Rheumatic diseases (RD) cause physical disability that may lead to 
early retirement, generating high indirect costs to society. We estimate these costs 
in the Portuguese population approaching the statutory retirement age. Methods: 
Health, sociodemographic and occupational data was retrieved from the 4th 
National Health Survey (2005/2006), for all people between 50 and 64 years of age 
(3,762 men and 4,241 women), whilst an official wage national database was used 
to estimate productivity values by gender, age-group and region, using the human 
capital approach. The effects of RD on the likelihood of early retirement and the 
attributable fractions estimates were obtained at the individual level by logistic 
regression. Results: At the time of the survey, 37.2% of the population with ages 
50-64 years old self-reported at least one RD and among these 22.7% were officially 
retired, compared with 17.6% of those without RD (p< 0.001). Females had higher 
prevalence of RD (49.8% vs. 23.4% for males; p< 0.001). Presence of RD was associated 
with early retirement regardless of age, gender and region (OR= 1.3; CI 95%: 1.0 - 1.6). 
The estimated annual indirect costs following premature retirement attributable 
to RD were € 367 million (€ 504 per RD patient). Age-groups closer to the statutory 
retirement age contribute more to the overall indirect costs and also have higher 
individual productivity values. For instance, 60-64 years old age-group contribute 
with 52% of overall costs and had an average indirect cost of 699€ per RD patient. 
Females were responsible for about 55% of these costs, however males contrib-
ute with higher individual productivity losses (cost per patient: 788€ vs. 390€ , for 
males and females respectively). ConClusions: Annual early retirement indirect 
costs attributable to RD are considerable. These results highlight the need to target 
patients with rheumatic conditions in order to obtain health and productivity gains 
and reduce early retirement in society.
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objeCtives: Psoriatic arthritis (PsA) entails an individual burden to patients and 
ties up resources. This study aimed to assess the total costs of PsA, including the 
indirect burden of PsA patients in Hungary and to obtain an overview of patients’ 
status, demographics, morbidity, and working capacity. Methods: Between 
January–March 2014, a questionnaire survey was conducted among PsA patients 
and filled out voluntarily and anonymously. Missing data was not imputed in the 
analysis; considered patient number is presented next to results if lower than total 
patient number. Results: 145 patients completed the questionnaire, of which 57% 
were women. Mean age was 54 years (Standard Deviation [SD]: 14 years) and aver-
age disease duration was 17 years (SD: 11 years). At primary diagnosis of PsA, 79% 
of patients had a full-time job, 4% a part-time job and only 3% received disability 
pension. At time of survey, only 32% of patients worked full-time, 4% part-time, and 
the proportion of disability pensioners increased to 28%. Cost calculation results* 
showed that the average annual total cost per PsA patient was 3,842€ . Within this, 
average annual direct non-medical cost was approximately 1,318€ (141 patients) and 
average annual indirect cost per patient was approximately 2,635€ (142 patients). 
Wage loss due to disability pension generated the highest average annual indirect 
cost per patient (2,734€ – 119 patients). In the working-age population (95 patients, 
31–62 years) total average cost per patient was 5,334€ . ConClusions: PsA can 
cause patients to become partially or completely disabled, which imposes a signifi-
cant burden directly on their environment and indirectly to society. Average direct/
indirect costs are higher with longer disease duration and greater skin manifesta-
tions. Patients may already be driven out from the labour market in their active 
ages because of the disease’s symptoms and variability, leading to reduced social 
engagement. *exchange rate: 303,59HUF/EUR
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objeCtives: To evaluate the real life practice of the use of botulinum toxin A 
(BoNT-A) in post-stroke upper limb spasticity and the economic consequences of 
fair comparisons of the dosing between either abobotulinumtoxinA (Dysport®) or 
onabotulinumtoxinA (Botox®) or incobotulinumtoxinA (Xeomin®). Methods: 
ULIS-II is an observational, prospective study, conducted in 84 centers in 22 coun-
tries. Of 456 adults with post-stroke upper limb spasticity presenting for treatment 
with BoNT-A, 193 patients with the same injected limb segments “upper arm and 
lower arm” were analyzed for the dose injected for one cycle of BoNT-A. Treatment 
and concomitant interventions were in accordance with routine local clinical prac-
tice. Sample size, mean (SD)/median dose (min-max) in Unit for each BoNT-A and 
annual cost per patient were calculated using the mean dose administered and 
considering no vial sharing. An injection interval of 12 weeks was simulated for 
all BoNT-A treatments and the UK listed public price was used to ascertain annual 
cost. Results: For the abobotulinumtoxinA group (N= 141) a mean (SD)/median 
(min-max) dose of 665 U (280)/500 U (150-1500) was injected, for the onabotuli-
numtoxinA group (N= 37) a mean (SD)/median dose of 183 U (99)/200 U (50-500) 
was injected and for incobotulinumtoxinA (N= 15), a mean (SD)/median dose of 
